22:33 , Jun 21, 2017 |  BC Extra  |  Company News

Sarepta gets option for Genethon's DMD gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it gained an option to obtain exclusive U.S. rights from non-profit organization Genethon (Evry, France) to a gene therapy to treat Duchenne muscular dystrophy. The collaboration covers a Genethon preclinical program...
01:10 , May 13, 2017 |  BioCentury  |  Emerging Company Profile

Dialing down dynamin

Dynacure S.A.S. is developing an antisense oligonucleotide against DNM2 that could treat all three subtypes of centronuclear myopathy, two of which are not covered by industry’s pipeline. Centronuclear myopathy (CNM) is a group of rare congenital...